Dx & Vx Co., Ltd. 180400

Dx&Vx (DXVX, KRX: 180400), a biopharmaceutical company, announced that it signed two material transfer agreements (MTAs) in Latin America within a two-month span in July and August, both related to its room-temperature, long-term nucleic acid stabilization platform, KRNA. Following its first Latin American agreement with an Argentine biopharmaceutical company in July, the company signed a second agreement in August with one of the region's leading public health institutions, securing validation

Dx&Vx has successfully expanded its global partnering initiatives at the BIO International Convention 2026 (BIO USA), raising the visibility of its overseas out-licensing opportunities.